Key facts
- This page summarizes Michael D. Bookman's Form 4 filing for Immuneering Corp (IMRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Oct 2025, 08:52.
Michael D. Bookman - 01 Oct 2025 Form 4 Insider Report for Immuneering Corp (IMRX)
- Reporting relationship
- CHIEF LEGAL OFFICER, SECRETARY
- Issuer ticker
- IMRX
- Reported as of
- 01 Oct 2025
- Net transaction value
- +$6,966
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2025, 08:52:43 UTC
- Prior SEC filing
- 07 Feb 2025
- Next SEC filing
- 05 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael D. Bookman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael D. Bookman filed Form 4 for Immuneering Corp (IMRX) on 02 Oct 2025.
Change
- Previous filing in this sequence was filed on 07 Feb 2025.
- Current net transaction value: +$6,966.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001840339
Primary reporting owner
Bookman Michael
- Relationship
- CHIEF LEGAL OFFICER, SECRETARY
- Address
- 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
- Signature
- /s/ Michael D. Bookman
- Signature date
- 02 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMRX
transaction
Class A Common Stock
Purchase
- Transaction value
- $6,966
- Shares
- +1,020
- Change %
- +26%
- Price
- $6.83
- Shares after
- 4,870
- Date
- 01 Oct 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.